DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Detecting Central and Peripheral Biomarkers in MDD

Information source: Centre for Addiction and Mental Health
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depressive Disorder

Intervention: phenelzine treatment (Other)

Phase: N/A

Status: Recruiting

Sponsored by: Centre for Addiction and Mental Health

Official(s) and/or principal investigator(s):
Jeffrey H. Meyer, MD, PhD, Principal Investigator, Affiliation: Research Imaging Centre, Centre for Addiction and Mental Health

Overall contact:
Laura Miler, Phone: 416.535.8501, Ext: 34386


The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.

Clinical Details

Official title: Detecting Central and Peripheral Biomarkers in Major Depressive Disorder (MDD)

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: MAO-B VT levels measured with PET in MDE secondary to MDD

Detailed description: Subjects will receive a PET and MRI scan before and after treatment with phenelzine.


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- 18-80 years of age

- good physical health

- Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current

major depressive episode (MDE)

- DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a

psychiatric consultation

- greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).

- history of non-response to several different antidepressant classes

Exclusion Criteria:

- herbal, drug or medication use (that affect CNS function)

- suicide attempts

- drug or medication use within eight weeks (+5 half lives of medication)

- history of substance abuse or any neurotoxin use

- history of psychotic symptoms

- history of central nervous system (CNS) medical illness

- current substance abuse

- test positive on pregnancy test (for women)

Locations and Contacts

Laura Miler, Phone: 416.535.8501, Ext: 34386

Center for Addiction and Mental Health, Toronto, Ontario M5T 1R8, Canada; Recruiting
Laura Miler, Phone: 416-535-8501, Ext: 34386
Jeffrey Meyer, MD PhD, Principal Investigator
Additional Information

Information about research at the Centre for Addiction and Mental Health

Starting date: June 2014
Last updated: June 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017